Fig. 4

Mouse orthotopic HCC model reveals a synergistic activity of the avapritinib and Lenvatinib combination. (A) Mouse HCC orthotopic xenograft models were established with PDGFRA-overexpressing or control Hepa1-6-Luc cells and treated with lenvatinib or PBS as a control. Representative bioluminescent images of mice from the indicated groups are displayed. (B–D) Mice bearing PDGFRA-overexpressing Hepa1-6 orthotopic HCC models were treated with lenvatinib, avapritinib, or a combination of both. Representative bioluminescent images (B), survival curves (C), and body weight measurements (D) of mice from the indicated groups are presented. (E) Representative H&E staining and IHC images of PDGFRA and Ki67 in the orthotopic transplantation tumor model are shown